Experimental Malaria Vaccine Shows Lasting Protection in Clinical Trials
• An experimental malaria vaccine, PfSPZ Vaccine, demonstrated significant protection against parasite infection and clinical malaria for up to two years in healthy Malian adults.
• The vaccine also showed promise in protecting women from malaria during pregnancy, with efficacy rates ranging from 49% to 86% in an exploratory analysis.
• The trials, supported by the NIH, suggest that preconception immunization with PfSPZ Vaccine could be a new strategy to reduce mortality for women with malaria in pregnancy.
• Further research is planned to assess the safety and efficacy of PfSPZ Vaccine administered during pregnancy in larger clinical trials.
© Copyright 2025. All Rights Reserved by MedPath